KCT0001862进行中（未招募）未知
A randomized, open-label, oral single dosing, two-way crossover clinical trial to evaluate the effects of food on the bioavailability of CKD-397 after a single oral dose in healthy male subjects
Chong Kun Dang0 个研究点目标入组 16 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- Male
入选标准
- •1. Healthy male subject older than 19 years at the time of screening.
- •2. Subjects who BMI more than 17.5kg/m2 and less than 30.5kg/m2 and weight more than 55kg
- •3. Subjects who signed the informed consent form after understanding fully to hear a detailed explanation in the clinical trial
排除标准
- •1. Subjects who have a history of blood, kidneys, endocrine, respiratory, gastrointestinal, urinary,
- •cardiovascular, hepatic, psychiatric, neurological or allergic diseases that is clinically significant (Except untreated asymptomatic seasonal allergies at the time of administration)
- •2. Subjects who have a history of gastrointestinal disease or gastrointestinal surgery which can affect drug absorption.
- •3. Subjects who show AST or AST > 2 times upper limit of normal range or estimated Glomerular Filteration Rate(eGFR) < 60 mL/min/1.73m2
- •4. Subjects who drink Alcohol > 210g/week within 6 months prior to the screening.
- •5. Subjects who take the medication involved in other clinical trials or bioequivalence tests within three months before the first dose medication characters.
- •6. Subjects who show Systolic Blood Pressure =100 or =150 mmHg or Diastolic Blood Pressure =60 or =100 mmHg at screening
- •7. Subjects who have orthostatic hypotension
- •8. Subjects who have history of drug abuse or drug abuse positive at screening
- •9. Subjects who treated with metabolizing enzyme inducers or inhibitors such as barbitals within 30days prior to the first dosing.
- •10. Smoker ( = 20cigarettes/day)
- •11. Subjects who takes Ethical The Count(ETC) or herb medicine within two weeks or Over The Count(OTC) or vitamin supplement within 1 week before the first IP administration
- •12. Subjects who do the whole blood donation within two months or component blood donation within 1month prior to the first dosing or receive blood transfusion within 1month prior to the first dosing
- •13. Subjects who can increase risk due to clinical test and administration of drugs or has Severe grade / chronic medical, mental condition or abnormal laboratory result that may interfere with the analysis of test results
- •14. Subjects who take organic nitrate medicine regularly or intermittently
- •15. Patients with genetic degenerative retimal disease including retinitis pigmentosa
- •16. Subjects who have hypersensitivity to medicines including tadalafil/tamsulosin component or any other medicines(aspirin, antibiotics etc.) or medical history of clinically significant hypersensitivity
- •17. Patients who lost sight of one eye by Non-arteritic anterior ischemic optic neuropathy(NAION)
- •18. Subjects with hereditary diseases of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
- •19. Subjects who use a trustworthy method of contraception
- •20. Subjects who is not able to comply with guidelines described in the protocol
- •21. Subjects who is determined by investigator's decision including laboratory test result or another reason as unsuitable for clinical trial participation
研究者
相似试验
已完成
不适用
A clinical trial to compare safety and pharmacokinetic characteristics of CKD-337KCT0001787Chong Kun Dang48
已完成
不适用
Bioequivalence study of Dydrogesterone against DuphastoCTRI/2022/09/046057Medethix Inc28
尚未招募
不适用
Bioequialence study of two novel strengths of CoartemCTRI/2011/12/002256ovartis Healthcare Pvt Ltd120
已完成
Unknown
Phase 1 Trial to Evaluate the pharmacokinetic characteristics and safety/tolerability of coadministration (AD-2071 and AD-2072) or fixed-dose combination(AD-207) in healthy adult volunteersDiseases of the circulatory systemKCT0009354Addpharma56
招募中
不适用
The pharmacokinetic characteristics and safety of Rap18001 in postmenopausal femaleDiseases of the musculo-skeletal system and connective tissueKCT0004153Chonbuk National University Hospital6